Elite Pharmaceuticals (ELTP) Risk Analysis

373 Followers

Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F). Risk factors show the challenges a company faces. Investors can consider the worst-case scenarios before making an investment. TipRanks’ Risk Analysis categorizes risks based on proprietary classification algorithms and machine learning.

Elite Pharmaceuticals disclosed 40 risk factors in its most recent earnings report. Elite Pharmaceuticals reported the most risks in the “Finance & Corporate” category.

Risk Overview Q4, 2025

Risk Distribution

43% Finance & Corporate

30% Legal & Regulatory

15% Tech & Innovation

5% Production

5% Ability to Sell

3% Macro & Political

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

This chart displays the stock's most recent risk distribution according to category. TipRanks has identified 6 major categories: Finance & corporate, legal & regulatory, macro & political, production, tech & innovation, and ability to sell.

Risk Change Over Time

2022

S&P500 Average

Sector Average

Risks removed

Risks added

Risks changed

Elite Pharmaceuticals Risk Factors

New Risk (0)

Risk Changed (0)

Risk Removed (0)

No changes from previous report

The chart shows the number of risks a company has disclosed. You can compare this to the sector average or S&P 500 average.

The quarters shown in the chart are according to the calendar year (January to December). Businesses set their own financial calendar, known as a fiscal year. For example, Walmart ends their financial year at the end of January to accommodate the holiday season.

Risk Highlights Q4, 2025

Main Risk Category

Finance & Corporate

With 17 Risks

Finance & Corporate

With 17 Risks

Number of Disclosed Risks

No changes from last report

S&P 500 Average: 31

No changes from last report

S&P 500 Average: 31

Recent Changes

0Risks added

0Risks removed

0Risks changed

Since Dec 2025

0Risks added

0Risks removed

0Risks changed

Since Dec 2025

Number of Risk Changed

No changes from last report

S&P 500 Average: 3

No changes from last report

S&P 500 Average: 3

See the risk highlights of Elite Pharmaceuticals in the last period.

Risk Word Cloud

The most common phrases about risk factors from the most recent report. Larger texts indicate more widely used phrases.

Risk Factors Full Breakdown - Total Risks 40

Finance & Corporate

Total Risks: 17/40 (43%)Above Sector Average

Share Price & Shareholder Rights7 | 17.5%

Share Price & Shareholder Rights - Risk 1

Issuance of shares of common or preferred stock could make achieving a change of control more difficult.

The issuance of additional equity, including convertible instruments or preferred stock, may be used to deter hostile takeovers. However, such actions can also complicate potential corporate transactions and may reduce the attractiveness of our stock to potential investors.

Share Price & Shareholder Rights - Risk 2

Capital raises through sales of securities may cause substantial dilution to existing shareholders.

If we raise additional capital by issuing new shares, existing shareholders could experience significant dilution in their ownership percentage. This potential dilution may lead to a decline in the value of their investment and could negatively impact the market price of our common stock.

Share Price & Shareholder Rights - Risk 3

Our stock price has been volatile.

Our common stock has experienced significant price fluctuations due to various factors including market conditions, regulatory developments, litigation, and industry-specific risks. This volatility can negatively affect investor confidence and the overall perceived value of our shares.

Share Price & Shareholder Rights - Risk 4

Shareholder activism could negatively affect us.

Shareholder activism, including efforts to alter corporate governance, strategic direction, or management, may force management to divert attention, incur significant legal expenses, or implement changes that are not in the best interests of the company, thereby adversely impacting our business operations and share price.

Share Price & Shareholder Rights - Risk 5

Our common stock is a penny stock, quoted on the OTC bulletin board, with rules in place that could limit trading and liquidity of our shares, increased transaction costs that could adversely affect our price per share.

Being classified as a low-priced or penny stock subjects our common stock to additional regulatory requirements and trading restrictions that can limit liquidity, increase transaction costs, and contribute to higher price volatility. These factors may make it more difficult for investors to trade our shares at favorable prices.

Share Price & Shareholder Rights - Risk 6

Dilution from issuance of shares to Directors, Officers, Employees, Consultants or upon exercise of warrants and options or the perception that dilution may occur could cause the price per share of common stock to fall.

The issuance of additional shares through stock options, warrants, and other equity awards may dilute the ownership interest of existing shareholders. This dilution, or even the expectation of it, can depress the market price of our common stock and adversely affect investor confidence.

Share Price & Shareholder Rights - Risk 7

While we currently qualify as a smaller reporting company under SEC regulations, we cannot be certain, if we take advantage of the reduced disclosure requirements applicable to these companies, that we will not make our stock less attractive to investors. Once we lose smaller reporting company status, the costs and demands placed upon our management are expected to increase.

The SEC’s rules exempt smaller reporting companies from various disclosure requirements, including the omission of an auditor’s attestation on internal control over financial reporting. However, if our public float grows or if we lose smaller reporting company status, increased reporting obligations and related costs may arise, potentially making our stock less attractive to investors.

Accounting & Financial Operations6 | 15.0%

Accounting & Financial Operations - Risk 1

We have identified material weaknesses in our internal control over financial reporting which could, if not remediated, adversely affect our ability to report our financial condition, cash flows and results of operations in a timely and fairly stated manner and/or increase the risk of future misstatements, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Based on reviews conducted by management and guidance from third-party subject matter experts, we have concluded that material weaknesses in our internal controls exist. Although no material misstatement of historical financial statements was identified, if we are unable to remediate these weaknesses—or if new weaknesses emerge—our ability to report financial results in a timely and accurate manner may be impaired, potentially causing the market value of our common shares and/or debt securities to decline. Please see Item 9A 'Controls and Procedures' in Part II.

Accounting & Financial Operations - Risk 2

Our reporting and payment obligations under the Medicaid rebate program and other governmental purchasing programs are complex and subject to review.

We establish liabilities for sales allowances including discounts, returns, chargebacks, and rebates under Medicaid and other governmental programs. The methodologies used involve significant judgment. If our estimates prove inaccurate or if regulatory reviews determine noncompliance, we could face penalties or increased financial burdens that may materially affect our profitability.

Accounting & Financial Operations - Risk 3

GAAP requires estimates, judgements and assumptions which inherently contain uncertainties.

The preparation of our consolidated financial statements in accordance with GAAP involves making estimates, judgments, and assumptions that affect reported amounts of assets, liabilities, revenues, and expenses. Revisions to these assumptions or the need to adjust estimates in the future could lead to restatements of our financial results, which might adversely affect our business and stock price.

Accounting & Financial Operations - Risk 4

There is a risk of impairment of significant intangible assets on our balance sheet.

Intangible assets constitute a significant portion of our balance sheet—approximately $5.6 million or 6% of our assets as of March 31, 2025. GAAP mandates regular impairment reviews and should circumstances change, impairment charges may be required. Such impairments could adversely impact our profitability and financial condition.

Accounting & Financial Operations - Risk 5

We have no plans to pay regular dividends or conduct share purchases.

We do not intend to distribute regular cash dividends or repurchase our shares. Investors will need to rely on stock price appreciation for returns, which may not be realized if market conditions deteriorate or if our financial performance underperforms expectations.

Accounting & Financial Operations - Risk 6

We have a relatively limited operating history and our operating results could fluctuate significantly.

Our historical operating results have shown significant variability on a year-to-year and quarter-to-quarter basis due to factors such as the timing of FDA approvals, product launches, market acceptance, research and development expenditures, results of clinical trials, and changes in industry conditions. Negative fluctuations in any of these areas could have a material adverse effect on our business, financial condition, results of operations, cash flows, and stock price.

Debt & Financing4 | 10.0%

Debt & Financing - Risk 1

We have substantial indebtedness which may adversely affect our financial condition.

As of March 31, 2025, our total liabilities include various loans, leases, bonds, derivative liabilities and other payables amounting to $42.9 million. This substantial indebtedness increases our vulnerability to rising interest rates, requires significant cash flows for debt service, restricts our financial flexibility, and could lead to adverse consequences such as default or accelerated repayment, all of which may materially harm our financial condition.

Debt & Financing - Risk 2

We most likely will require additional financing to meet our business objectives.

Our planned initiatives, including clinical development and the commercialization of new products, are capital intensive. If the cash generated from our current operations is insufficient, we will need to raise additional financing. Failure to secure timely and favorable capital may limit our ability to execute our strategic plans and result in a material adverse effect on our profitability.

Debt & Financing - Risk 3

Our ability to fund operations is uncertain and we may require additional financing to meet objectives.

We rely on generated cash flows and market access to fund our operations, product development, and other business activities. However, uncertainties in obtaining financing—due to market conditions, credit availability, or other factors—could adversely affect our liquidity, restrict our ability to meet financial obligations, and ultimately harm our business performance.

Debt & Financing - Risk 4

The DEA could limit the availability of active ingredients used in many of our products.

The Drug Enforcement Administration regulates controlled substances and may impose quotas or restrictions on the procurement of active pharmaceutical ingredients used in our products. Any such limitations or delays could impair our production capabilities, postpone clinical trials or product launches, and have a material adverse effect on our business.

Legal & Regulatory

Total Risks: 12/40 (30%)Above Sector Average

Regulation9 | 22.5%

Regulation - Risk 1

Regulatory factors may cause us to be unable to manufacture products or face interruptions in our manufacturing process.

If our manufacturing facilities—or those of our suppliers—fail to comply with regulatory demands such as FDA's cGMP standards or DEA requirements, our ability to produce and supply products could be disrupted. Such regulatory noncompliance or interruptions could lead to production delays, increased costs, and a material adverse effect on our business operations.

Regulation - Risk 2

We received a CRL from the FDA indicating that the SequestOx™ NDA is not ready for approval.

The FDA issued a Complete Response Letter (CRL) stating that the SequestOx™ NDA is not ready for approval in its present form. Consequently, development of SequestOx™ has been paused, and there is uncertainty regarding whether necessary modifications and studies will enable future approval. This situation could result in a material adverse impact on our investment in SequestOx™ and delay its commercialization.

Regulation - Risk 3

We are subject to various fraud and abuse laws which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

Our operations are regulated by laws such as the federal Anti-Kickback Statute, the False Claims Act, and HIPAA. Noncompliance—even if inadvertent—could result in severe penalties including fines, exclusion from government healthcare programs, and costly litigation. Such outcomes would have a material adverse impact on our financial condition.

Regulation - Risk 4

Agreements between branded pharmaceutical companies and generic pharmaceutical companies are facing increased government scrutiny in the United States and internationally.

Settlement agreements and licensing arrangements between brand and generic companies are subject to review by antitrust authorities such as the FTC and DOJ. Increased governmental scrutiny in this area could result in antitrust investigations, potentially leading to changes in our agreements or legal actions that may adversely affect our revenue and operations.

Regulation - Risk 5

Our manufacturing operations and those of our suppliers are subject to FDA registration and periodic inspections.

Our ability to produce and distribute our products depends on maintaining current FDA (and if applicable, DEA) registrations and licenses. Failure to comply with manufacturing regulations or adverse inspection findings could lead to disruptions in production, delays in product availability, and a material adverse effect on our business.

Regulation - Risk 6

Once a product is approved or cleared for marketing, failure to comply with applicable regulatory requirements can result in significant consequences.

After a product receives regulatory approval, companies must continue to comply with ongoing requirements such as post-marketing studies, safety reporting, and adherence to labeling and manufacturing standards. Any failure to meet these requirements might trigger product recalls, regulatory enforcement actions, fines, or other sanctions that can materially harm our operations and reputation.

Regulation - Risk 7

The ANDA approval process for a new product varies in time and is difficult to estimate.

The approval timeline for an Abbreviated New Drug Application (ANDA) can vary dramatically, from as little as 10 months to several years, due to factors such as application completeness and FDA review processes. This uncertainty can delay product launches and adversely affect our anticipated revenue streams.

Regulation - Risk 8

We may seek FDA approval for certain product candidates through the 505(b)(2) regulatory pathway. Even if we receive approval for an NDA under Section 505(b)(2)...

The 505(b)(2) pathway offers a route to FDA approval by relying on existing data; however, there remains uncertainty regarding the extent of any de facto marketing exclusivity and our ability to recoup invested costs. Additionally, objections to the FDA’s interpretation of Section 505(b)(2) could delay or even prevent approval of our new product applications.

Regulation - Risk 9

The pharmaceutical industry is heavily regulated which creates uncertainty and substantial compliance costs.

Governmental authorities such as the FDA impose comprehensive and evolving requirements on drug development, manufacturing, labeling, marketing, and distribution. In addition, obtaining regulatory approval for generic products requires additional bioequivalence studies and research. This complex regulatory environment creates uncertainty and imposes significant compliance costs, any of which could delay product launches and adversely impact our operations.

Litigation & Legal Liabilities3 | 7.5%

Litigation & Legal Liabilities - Risk 1

Investigations and litigation concerning the calculation of average wholesale prices may adversely affect our business.

Government and third-party payers rely on average wholesale price (AWP) calculations for drug reimbursement. Disputes or litigation arising from claims that AWPs are inflated can lead to significant legal costs, potential penalties, and adverse financial impacts on our business.

Litigation & Legal Liabilities - Risk 2

Public concern over the abuse of opioid medications, including increased legal and regulatory action, could also negatively affect our business.

Heightened public and regulatory scrutiny regarding the abuse of opioid medications could lead to increased investigations, lawsuits, and restrictions. This environment may force reductions in orders or limitations in the commercialization of our opioid products, thereby negatively impacting our business, financial condition, and reputation.

Litigation & Legal Liabilities - Risk 3

Litigation, product liability claims, government investigations and other significant legal proceedings are common in the pharmaceutical industry.

The pharmaceutical sector is inherently subject to litigation and legal challenges including product liability claims, government enforcement actions, and class actions. Even with strong legal defenses, such proceedings can be lengthy, costly, and distracting, potentially resulting in substantial financial liabilities and negative effects on our business.

Tech & Innovation

Total Risks: 6/40 (15%)Below Sector Average

Innovation / R&D1 | 2.5%

Innovation / R&D - Risk 1

Delays in generic product development may result in failure to achieve adequate return on investment.

The development process for generic pharmaceuticals—which includes formulation, testing, and obtaining FDA review and approval—is lengthy and capital intensive. Any delays in this process may reduce the period during which significant profits can be achieved, thereby affecting our ability to generate an adequate return on investment.

Trade Secrets3 | 7.5%

Trade Secrets - Risk 1

Litigation concerning intellectual property, including disputes over patent infringement, could be costly and divert resources.

We face the risk of litigation from third parties alleging infringement of their intellectual property rights. Defending against such claims can be extremely expensive and time-consuming, with an uncertain outcome, and may result in significant financial liabilities or restrictions on our ability to commercialize our products.

Trade Secrets - Risk 2

We rely on trade secrets, unpatented proprietary expertise and continuing innovation, and any breach or inadequate protection could harm our business.

Although we use confidentiality agreements and other measures to protect our proprietary information, there is a risk that such information could be disclosed or independently developed by others. Loss of trade secrets or proprietary know-how may erode our competitive advantage and adversely affect our profitability.

Trade Secrets - Risk 3

Our ability to protect intellectual property rights and successfully defend against third-party allegations of IP infringement is vital to our business and uncertain.

Our competitive advantage depends on our ability to secure and enforce patents and maintain trade secret protections. If we are unable to protect our proprietary technology or if third parties successfully claim infringement, competitors may capture market share, which could result in lower revenues and a diminished competitive position.

Cyber Security1 | 2.5%

Cyber Security - Risk 1

Our operations could be disrupted by failure of our information systems or cyber-attacks.

Our business relies on robust IT systems to manage critical functions including manufacturing, logistics, finance, and communications. Significant disruptions or breaches due to cyber-attacks could compromise confidential data, interfere with business operations, and result in material adverse effects on our financial performance and reputation.

Technology1 | 2.5%

Technology - Risk 1

Artificial intelligence based platforms may present new risks and challenges to our business.

The adoption and integration of AI technologies into our operations could introduce new risks, such as data privacy issues, biased decision-making, system malfunctions, and challenges in interpreting complex outputs. These new risks may lead to unforeseen liabilities and operational disruptions, adversely impacting our business.

Production

Total Risks: 2/40 (5%)Below Sector Average

Supply Chain1 | 2.5%

Supply Chain - Risk 1

We depend to a large extent on third-party suppliers and distributors for the raw materials for our products.

A substantial portion of our manufacturing inputs, particularly active pharmaceutical ingredients (APIs), is sourced from third parties. Disruptions in the supply chain, supplier discontinuations, or delays in obtaining necessary regulatory approvals from suppliers can lead to higher costs or production delays, which may materially harm our business.

Costs1 | 2.5%

Costs - Risk 1

We may not be able to obtain or maintain adequate insurance coverages.

The cost of insurance—encompassing directors and officers, workers' compensation, product liability, and more—has increased markedly. Inadequate or deteriorating coverage, higher deductibles, or future premium hikes could leave us exposed to financial losses from claims or litigation, adversely influencing our business and stock price.

Ability to Sell

Total Risks: 2/40 (5%)Below Sector Average

Demand1 | 2.5%

Demand - Risk 1

Our business is dependent on market acceptance of our products and social and political pressures, including public concern over the abuse of opioids, may adversely affect our business.

The market acceptance of our products by physicians, patients, and payers is crucial for our commercial success. Factors such as clinical safety, efficacy, convenience, and cost effectiveness influence market adoption. In addition, ongoing social and political pressures related to opioid abuse may dampen demand for our products, resulting in decreased revenues and profitability.

Brand / Reputation1 | 2.5%

Brand / Reputation - Risk 1

Market perceptions of our business are important to us, especially regarding the safety and quality of our products.

The commercial success of our products is heavily dependent on market perceptions. If adverse events, recalls, or negative publicity occur—even if they are mistakenly attributed to our products—consumer confidence may decline. Such shifts in perception could reduce demand, harm our reputation, and have a material adverse effect on our business and financial performance.

Macro & Political

Total Risks: 1/40 (3%)Below Sector Average

Capital Markets1 | 2.5%

Capital Markets - Risk 1

New tariffs and evolving trade policy between the US and other countries may adversely affect our business.

Changes in tariffs, trade restrictions, and evolving international trade policies—particularly involving key trading partners such as China and Mexico—could disrupt our supply of critical raw materials. Such disruptions may lead to increased costs, delays in production, and an adverse impact on our overall business performance.

See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

FAQ

What are “Risk Factors”?

Risk factors are any situations or occurrences that could make investing in a company risky.

The Securities and Exchange Commission (SEC) requires that publicly traded companies disclose their most significant risk factors. This is so that potential investors can consider any risks before they make an investment.

They also offer companies protection, as a company can use risk factors as liability protection. This could happen if a company underperforms and investors take legal action as a result.

It is worth noting that smaller companies, that is those with a public float of under $75 million on the last business day, do not have to include risk factors in their 10-K and 10-Q forms, although some may choose to do so.

How do companies disclose their risk factors?

Publicly traded companies initially disclose their risk factors to the SEC through their S-1 filings as part of the IPO process.

Additionally, companies must provide a complete list of risk factors in their Annual Reports (Form 10-K) or (Form 20-F) for “foreign private issuers”.

Quarterly Reports also include a section on risk factors (Form 10-Q) where companies are only required to update any changes since the previous report.

According to the SEC, risk factors should be reported concisely, logically and in “plain English” so investors can understand them.

How can I use TipRanks risk factors in my stock research?

Use the Risk Factors tab to get data about the risk factors of any company in which you are considering investing.

You can easily see the most significant risks a company is facing. Additionally, you can find out which risk factors a company has added, removed or adjusted since its previous disclosure. You can also see how a company’s risk factors compare to others in its sector.

Without reading company reports or participating in conference calls, you would most likely not have access to this sort of information, which is usually not included in press releases or other public announcements.

A simplified analysis of risk factors is unique to TipRanks.

What are all the risk factor categories?

TipRanks has identified 6 major categories of risk factors and a number of subcategories for each. You can see how these categories are broken down in the list below.

1. Financial & Corporate

Accounting & Financial Operations - risks related to accounting loss, value of intangible assets, financial statements, value of intangible assets, financial reporting, estimates, guidance, company profitability, dividends, fluctuating results.
Share Price & Shareholder Rights – risks related to things that impact share prices and the rights of shareholders, including analyst ratings, major shareholder activity, trade volatility, liquidity of shares, anti-takeover provisions, international listing, dual listing.
Debt & Financing – risks related to debt, funding, financing and interest rates, financial investments.
Corporate Activity and Growth – risks related to restructuring, M&As, joint ventures, execution of corporate strategy, strategic alliances.

2. Legal & Regulatory

Litigation and Legal Liabilities – risks related to litigation/ lawsuits against the company.
Regulation – risks related to compliance, GDPR, and new legislation.
Environmental / Social – risks related to environmental regulation and to data privacy.
Taxation & Government Incentives – risks related to taxation and changes in government incentives.

3. Production

Costs – risks related to costs of production including commodity prices, future contracts, inventory.
Supply Chain – risks related to the company’s suppliers.
Manufacturing – risks related to the company’s manufacturing process including product quality and product recalls.
Human Capital – risks related to recruitment, training and retention of key employees, employee relationships & unions labor disputes, pension, and post retirement benefits, medical, health and welfare benefits, employee misconduct, employee litigation.

4. Technology & Innovation

Innovation / R&D – risks related to innovation and new product development.
Technology – risks related to the company’s reliance on technology.
Cyber Security – risks related to securing the company’s digital assets and from cyber attacks.
Trade Secrets & Patents – risks related to the company’s ability to protect its intellectual property and to infringement claims against the company as well as piracy and unlicensed copying.

5. Ability to Sell

Demand – risks related to the demand of the company’s goods and services including seasonality, reliance on key customers.
Competition – risks related to the company’s competition including substitutes.
Sales & Marketing – risks related to sales, marketing, and distribution channels, pricing, and market penetration.
Brand & Reputation – risks related to the company’s brand and reputation.

6. Macro & Political

Economy & Political Environment – risks related to changes in economic and political conditions.
Natural and Human Disruptions – risks related to catastrophes, floods, storms, terror, earthquakes, coronavirus pandemic/COVID-19.
International Operations – risks related to the global nature of the company.
Capital Markets – risks related to exchange rates and trade, cryptocurrency.